ArticleJournal of immunology (Baltimore, Md. : 1950)2018

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.

Adam Palazzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.